Form 4: Altimmune Director Boosts Stake with Share Purchase

Altimmune Director Catherine A. Sohn purchased 500 shares of common stock, increasing her direct beneficial ownership to 1,500 shares.

Summary

• Catherine A. Sohn, a Director of Altimmune, Inc., acquired 500 shares of the company's common stock.
• The transaction occurred on January 5, 2026, at a price of $4.2351 per share.
• Following this purchase, Ms. Sohn directly beneficially owns a total of 1,500 shares of Altimmune common stock.
• The transaction was made pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 7

Explanation: The insider purchase by a director is a positive signal, indicating management's confidence in the company's future performance and valuation.

Positives

• A director's purchase of company stock signals confidence in the company's current valuation and future prospects.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned investment strategy.

Industry Context

NA

Related Party Transactions

• Catherine A. Sohn, a Director of Altimmune, Inc., purchased 500 shares of the company's common stock directly from the market.

Stakeholder Impact

• Shareholders may interpret the director's purchase as a positive indicator of the company's health and future growth potential, potentially boosting investor confidence.

Key Dates

Recommendation

A director's direct purchase of company stock, especially under a Rule 10b5-1 plan, typically signals strong conviction in the company's long-term value and prospects, making it a favorable signal for potential investors.

Keywords

Altimmune, ALT, insider trading, Form 4, director purchase, common stock, beneficial ownership, Rule 10b5-1